67 research outputs found
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer
We previously reported that miR-1 is among the most consistently down-regulated miRs in primary human prostate tumors. In this follow-up study, we further corroborated this finding in an independent data set and made the novel observation that miR-1 expression is further reduced in distant metastasis and is a candidate predictor of disease recurrence. Moreover, we performed in vitro experiments to explore the tumor suppressor function of miR-1. Cell-based assays showed that miR-1 is epigenetically silenced in human prostate cancer. Overexpression of miR-1 in these cells led to growth inhibition and down-regulation of genes in pathways regulating cell cycle progression, mitosis, DNA replication/repair and actin dynamics. This observation was further corroborated with protein expression analysis and 3′-UTR-based reporter assays, indicating that genes in these pathways are either direct or indirect targets of miR-1. A gene set enrichment analysis revealed that the miR-1-mediated tumor suppressor effects are globally similar to those of histone deacetylase inhibitors. Lastly, we obtained preliminary evidence that miR-1 alters the cellular organization of F-actin and inhibits tumor cell invasion and filipodia formation. In conclusion, our findings indicate that miR-1 acts as a tumor suppressor in prostate cancer by influencing multiple cancer-related processes and by inhibiting cell proliferation and motility
A comparison of complications between ultrasound-guided prostate brachytherapy and open prostate brachytherapy
Detection of latent prostate cancer from routine screening: Comparison with breast cancer screening
Salvage external beam radiotherapy for locally recurrent prostate cancer after definitive brachytherapy
Impact of delaying 5-alpha reductase inhibitor therapy in men on alpha-blocker therapy to treat BPH: assessment of acute urinary retention and prostate-related surgery
PC10. Selective Nonoperative and Delayed Operative Approaches for the Management of Grade III Blunt Traumatic Aortic Injury
Off-Label Use of Exenatide for the Management of Insulin-Resistant Type 1 Diabetes Mellitus in an Obese Patient with Human Immunodeficiency Virus Infection
- …
